Uniqure NV
F:UQ1

Watchlist Manager
Uniqure NV Logo
Uniqure NV
F:UQ1
Watchlist
Price: 19.91 EUR -1.29%
Market Cap: 965.5m EUR

Uniqure NV
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Uniqure NV
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Uniqure NV
NASDAQ:QURE
Revenue
$15.8m
CAGR 3-Years
-36%
CAGR 5-Years
21%
CAGR 10-Years
7%
Pharming Group NV
AEX:PHARM
Revenue
$362.3m
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
30%
ProQR Therapeutics NV
NASDAQ:PRQR
Revenue
€16.1m
CAGR 3-Years
65%
CAGR 5-Years
11%
CAGR 10-Years
20%
argenx SE
XBRU:ARGX
Revenue
$3.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Revenue
$56.6m
CAGR 3-Years
7%
CAGR 5-Years
15%
CAGR 10-Years
36%
LAVA Therapeutics NV
NASDAQ:LVTX
Revenue
$12m
CAGR 3-Years
34%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Uniqure NV
Glance View

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

UQ1 Intrinsic Value
21.41 EUR
Undervaluation 7%
Intrinsic Value
Price

See Also

What is Uniqure NV's Revenue?
Revenue
15.8m USD

Based on the financial report for Sep 30, 2025, Uniqure NV's Revenue amounts to 15.8m USD.

What is Uniqure NV's Revenue growth rate?
Revenue CAGR 10Y
7%

Over the last year, the Revenue growth was -45%. The average annual Revenue growth rates for Uniqure NV have been -36% over the past three years , 21% over the past five years , and 7% over the past ten years .

Back to Top